Trial Profile
A Randomised, double-blind, placebo controlled, multi-centre phase II study to assess the Efficacy and safety of 2nd line Olaparib in combination with Paclitaxel, in Western patients with advanced gastric and gastro-oesophageal junction cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2019
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms OPERa
- 15 Jun 2019 Status changed from recruiting to discontinued.
- 24 Aug 2015 New trial record